Potential of Stem Cell-Derived Extracellular Vesicles in Treating Liver Disease
Author Information
Author(s): Zou Xue, Brigstock David
Primary Institution: Center for Clinical and Translational Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital
Hypothesis
Can mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) reduce the key pathogenic pathways of metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH)?
Conclusion
MSC-EVs are promising therapeutic agents for treating MASLD/MASH, but further studies are needed to validate their clinical applicability.
Supporting Evidence
- MSC-EVs have been shown to counteract oxidative stress, a significant contributor to liver injury.
- MSC-EVs may improve therapeutic efficacy for MASLD/MASH by delivering specific cargo components.
- Further studies are necessary to validate the clinical applicability and efficacy of MSC-EVs in human patients.
Takeaway
Scientists are studying tiny bubbles called extracellular vesicles from stem cells to see if they can help treat liver diseases caused by fat buildup.
Methodology
The review summarizes pre-clinical evidence showing the effects of MSC-EVs on liver disease models, identified through a literature search on PubMed.
Limitations
The review highlights that many studies do not adequately reflect the full pathological spectrum of MASH, especially regarding fibrosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website